Skip to main content

Piper Sandler Sticks to Its Buy Rating for Opko Health (OPK)

Tipranks - Tipranks - Sat Feb 28, 7:17AM CST

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Opko Health, with a price target of $3.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Tenthoff is a 4-star analyst with an average return of 4.9% and a 40.20% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Arrowhead Pharmaceuticals, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Opko Health with a $3.00 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Opko Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $148.5 million and a GAAP net loss of $31.3 million. In comparison, last year the company earned a revenue of $183.64 million and had a net profit of $14.03 million

Read More on OPK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).